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Leukotriene B
 
4
 
 is a lipid mediator that recently has been shown to have potent chemotactic 
activity for effector T lymphocytes mediated through its receptor, BLT1. Here, we developed 
a novel murine model of acute lung rejection to demonstrate that BLT1 controls effector 
CD8
 
 
 
 T cell trafficking into the lung and that disruption of BLT1 signaling in CD8
 
 
 
 T cells 
reduces lung inflammation and mortality in the model. In addition, we used BLT1-deficient 
mice and a BLT1 antagonist in two tracheal transplant models of lung transplantation to 
demonstrate the importance of BLT1 for the recruitment of T cells into tracheal allografts. 
We also show that BLT1-mediated CD8
 
 
 
 T cell recruitment plays an important role in the 
development of airway fibroproliferation and obliteration. Finally, in human studies of lung 
transplant recipients, we found that BLT1 is up-regulated on T lymphocytes isolated from 
the airways of patients with obliterative bronchiolitis. These data demonstrate that BLT1 
contributes to the development of lung rejection and obliterative bronchiolitis by mediating 
effector T lymphocyte trafficking into the lung. This is the first report that describes a 
pathologic role for BLT1-mediated T lymphocyte recruitment in disease and identifies BLT1 
as a potential therapeutic target after lung transplantation.
 
Leukotriene B
 
4
 
 (LTB
 
4
 
) is a lipid mediator de-
rived from arachidonic acid with potent chemo-
tactic activity for granulocytes and monocytes,
mediated through its G protein-coupled seven-
transmembrane-spanning receptor, BLT1 (1).
Recently we have demonstrated that LTB
 
4
 
 also
has potent chemotactic activity for in vitro–
activated  effector CD4
 
 
 
 and CD8
 
 
 
 lympho-
cytes; this activity also was mediated through
BLT1 (2, 3). In addition, in a murine model of
asthma, BLT1
 
 
 
/
 
 
 
 mice had an early defect in
CD4
 
 
 
 and CD8
 
 
 
 T lymphocyte recruitment
into the airways; however, this defect did not
persist and had no overall effect on the develop-
ment of airway inflammation and hyper-respon-
siveness in the model (3). These data suggest
that BLT1 may be important for lymphocyte re-
cruitment into the lung in certain disorders, but
it is unclear if BLT1-mediated lymphocyte re-
cruitment is of any pathologic consequence. We
hypothesized that the LTB
 
4
 
/BLT1 pathway
might be critical for the development of diseases,
such as lung transplant rejection, in which effec-
tor T lymphocytes directly mediate tissue injury.
Of note, in animal models of heart, liver, and
kidney transplantation, allograft rejection has
been shown to be mediated in part by LTB
 
4
 
/
BLT1 (4–7). However, these studies did not
clearly demonstrate the mechanism by which
LTB
 
4
 
 contributes to the rejection of allografts,
nor did they specifically look at lymphocyte
trafficking. We propose that in these previous
studies, inhibition of BLT1-mediated lympho-
cyte recruitment might have been the mecha-
nism that prolonged graft survival.
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Lung transplantation remains the only effective therapy
for the large number of patients with end-stage lung disease
(8, 9). However, despite advances in immunosuppressive
therapies and surgical techniques, overall 5-yr survival re-
mains only 50% (10). Mortality after lung transplantation re-
sults mainly from the development of chronic graft dysfunc-
tion from obliterative bronchiolitis (OB), which develops in
 
 
 
60% of lung transplant recipients (11–13). The histologic
hallmark of OB is an inflammatory and fibroproliferative re-
sponse in the small airways that can lead to significantly re-
duced lung function and death. Clinical studies have impli-
cated acute rejection (AR) as the major causative factor for
the development of OB (14–16). AR is orchestrated primar-
ily by activated graft-specific T lymphocytes (17), which ini-
tiate a cascade of events that leads to an intense inflammatory
reaction resulting in damage to the transplanted organ. It is
thought that effector T lymphocytes specific for airway epi-
thelial cells traffic into the airway and damage the airway ep-
ithelium; this damage then leads to an exuberant repair pro-
cess and OB (18, 19). Thus, donor-specific T lymphocyte
infiltration in AR is probably crucial for the subsequent de-
velopment of OB (20–22). Support for this hypothesis has
come from experiments that have demonstrated donor-spe-
cific T lymphocytes in bronchoalveolar lavage (BAL) fluid
and lung tissue taken from transplant recipients with OB (20,
23). It follows that interventions that block lymphocyte re-
cruitment into allografts should reduce the intensity of rejec-
tion and delay the development of OB.
In this study, we investigated the role of the LTB
 
4
 
/BLT1
pathway in effector T lymphocyte recruitment into the lung
during rejection of the airways. We used BLT1-deficient
mice (BLT1
 
 
 
/
 
 
 
) as well as mice treated with a specific small-
molecule antagonist of BLT1 (24) in three murine models of
airway rejection, including a novel murine model of anti-
gen-specific T cell–mediated lung injury. These experiments
demonstrated that disruption of BLT1 signaling not only re-
duced effector T cell trafficking into the lung but also dimin-
ished mortality and the pathologic changes induced by air-
way rejection. In addition, we demonstrated that BLT1 is
up-regulated on human T lymphocytes infiltrating the grafts
of lung transplant recipients with OB, which is the first
demonstration of BLT1 expression on human lymphocytes.
These data provide a definitive link between BLT1-medi-
ated lymphocyte recruitment and the pathogenesis of an in-
flammatory disease. Furthermore, the findings suggest that
BLT1 is a potential therapeutic target in lung transplant re-
jection and OB.
 
RESULTS
A novel murine model of effector CD8
 
 
 
 T cell–mediated 
lung rejection
 
To create a novel model of lung rejection that involved the
entire intact lung, we generated transgenic mice that specifi-
cally expressed a membrane-bound exogenous antigen,
chicken OVA, on airway-lining cells in the lung. Lung-spe-
cific injury then was induced by adoptive transfer of acti-
vated OVA-specific T cells. Lung-specific expression was
achieved by ligating the OVA gene behind the promoter for
rat Clara cell secretory protein (CC10) (Fig. 1 A) (25).
 CC10 is specifically expressed in Clara cells, which are
lung-specific cells that make up 50–60% of the lining of the
conducting airways in the mouse (26). The construct was
used to generate five strains of transgenic mice, which devel-
oped normally and had no abnormal pathology. The line
with the highest copy number of the transgene was chosen
for analysis and called CC10-OVA. Quantitative PCR
(QPCR) analysis of the RNA isolated from organs from
these mice demonstrated high-level expression of the trans-
gene only in the lungs and thymus (Fig. 1 B).
To induce rejection, we isolated CD8
 
 
 
 T cells from
OT-I mice, which are transgenic for a TCR specific for the
OVA peptide SIINFEKL bound to the class I MHC H-2K
 
b
 
(27). These cells were activated in vitro with IL-2 and IL-12
to generate effector CD8
 
 
 
 lymphocytes (28). Flow cytome-
Figure 1. A novel model of acute lung rejection. (A) Schematic of 
the transgene construct used to generate transgenic CC10-OVA mice. A 
segment of the OVA gene containing the epitope recognized by OT-I cells 
was ligated to the transmembrane (TM) domain of the human transferrin 
receptor and the CC10 promoter. (B) OVA RNA levels in the indicated 
organs as measured by QPCR analysis and expressed as copies per copy 
of GAPDH. WT, wild type. (C) Mortality of wild-type mice and CC10-OVA 
transgenic mice after adoptive transfer of 5   105 effector OT-I cells 
(n   6 mice/group). 
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try of these cells demonstrated an effector phenotype: low
CD62L expression, high CD25 expression, high perforin
expression, and high IFN
 
 
 
 expression (Fig. S1 A, available at
http://www.jem.org/cgi/content/full/jem.20042481/DC1,
and unpublished data). Further analysis of these cells demon-
strated BLT1 mRNA expression (Fig. S2 A, available at http:
//www.jem.org/cgi/content/full/jem.20042481/DC1) and
efficient chemotaxis to LTB
 
4
 
 (Fig. S2 B). Chemotaxis to
LTB
 
4
 
 was progressively inhibited by increasing doses of CP
105,696, a specific BLT1 antagonist (Fig. S2 B and reference
24). Adoptive transfer of 5 
 
 
 
 10
 
5
 
 effector OT-I cells into the
CC10-OVA mouse led to death in 100% of mice by 6 d
(Fig. 1 C). Injection of these cells into wild-type mice did
not result in illness or mortality (Fig. 1 C). The OT-I mice
Figure 2. Induction of lung inflammation of CC10-OVA mice. 
(A) Analysis by flow cytometry of BAL, lung, thoracic lymph node (TLN), and 
spleen (Sp) tissue for OT-I cells 3 and 5 d after transfer. The transferred cells 
are identified by Thy1.1  staining. Numbers are the percentage of positive 
cells in the lymphocyte gate. Graphs are representative of results from n   6 
mice. (B) Total OT-I lymphocyte counts in the BAL and lungs of wild-type 
and CC10-OVA mice 5 d after adoptive transfer (n   3 mice/group). Cells 
were analyzed by flow cytometry. (C) Representative lung histology from 
wild-type mice 3 d (i and ii) and 5 d (v and iv) after adoptive transfer of 
effector OT-I cells and from CC10-OVA transgenic mice 3 d (iii and iv.) and 
5 d (vii and viii) after adoptive transfer of effector OT-I cells. Low power at 
40x, high power at 400x. Arrows indicate inflammation around airways. 
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were in a Thy1.1
 
 
 
 background allowing us to track the
transferred cells in the CC10-OVA mouse, which is in a
Thy1.2
 
 
 
 background. Analysis of BAL, lung tissue, spleen,
and thoracic lymph nodes 3 and 5 d after transfer revealed
accumulation of the OT-I cells in the BAL and lung and re-
duced numbers of the cells in the spleen and lymph node of
CC10-OVA mice when compared with wild-type mice
(Fig. 2 A).
At 5 d there was a 400-fold and threefold increase in the
number of OT-I cells in the BAL and lung, respectively, of
CC10-OVA mice compared with wild-type mice (Fig. 2 B).
Histological analysis of the lung demonstrated perivascular and
peribronchial inflammation 3 d after adoptive transfer (Fig. 2
C, iii and iv) that progressed to diffuse infiltration of the lung
5 d after adoptive transfer (Fig. 2 C, vii and viii). Adoptive
transfer of OT-I effector cells into nontransgenic wild-type
mice did not induce significant inflammation of the lung at 3,
5, and 14 d (Fig. 2 C, i, ii, v, and vi and data not depicted).
 
BLT1-deficient T cells induce reduced mortality 
and lung inflammation
 
To characterize further the precise role of BLT1 in lympho-
cyte recruitment in lung rejection, we crossed the OT-I
strain with BLT1
 
 
 
/
 
 
 
 mice to generate OT-I/BLT1
 
 
 
/
 
 
 
 mice
(3). CD8
 
 
 
 lymphocytes generated from these mice prolifer-
ated normally and had similar staining for activation markers,
perforin, and IFN
 
 
 
 compared with OT-I/BLT1
 
 
 
/
 
 
 
 cells
(Fig. S1 B and not depicted). CC10-OVA mice that re-
ceived OT-I/BLT1
 
 
 
/
 
 
 
 effectors had significantly reduced
mortality (Fig. 3 A), longer median survival (7 d vs. 5 d, log-
rank analysis, P 
 
 
 
 0.0001), and had reduced inflammation of
the lung as assessed by histological analysis (Fig. 3 B, ii and
iv) compared with CC10-OVA mice that received OT-I/
BLT1
 
 
 
/
 
 
 
 cells (Fig. 3 B, i and iii).
Mice that received OT-I/BLT1
 
 
 
/
 
 
 
 CD8
 
 
 
 effector cells
had mild inflammation around the vasculature in the lung
(black arrows) and almost no involvement of the airways
(white arrows). The OT-I/BLT1
 
 
 
/
 
 
 
 mice are in the same
Thy1.2
 
 
 
 background as the CC10-OVA mice, so we used a
Figure 3. Reduced mortality and inflammation after adoptive 
transfer of OT-I/BLT1 /  cells into CC10-OVA mice. (A) Mortality of 
CC10-OVA transgenic mice injected with effector OT-I/BLT1 /  cells and 
CC10-OVA transgenic mice injected with effector OT-I/BLT1 /  cells (n   11 
mice injected with OT-I/BLT1 /  cells and n   13 mice injected with OT-I/
BLT1 /  cells). Curves were significantly different by log-rank test. (B) Rep-
resentative histology of a CC10-OVA transgenic mouse 3 d after adoptive 
transfer of effector OT-I/BLT1 /  cells (i and iii) and a CC10-OVA transgenic 
mouse 3 d (ii and iv) after adoptive transfer of effector OT-I/BLT1 /  cells. 
Low power at 40x (i and ii), high power at 400x (iii and iv). Black arrows 
indicate pulmonary vasculature; white arrows indicate airways.
Figure 4. Decreased recruitment and cytotoxicity of OT-I/BLT1 /  
cells. (A) The number of OT-I cells (CD8 /OT-I TCR-specific tetramer-positive) 
recruited into the BAL of CC10-OVA mice after the transfer of either effector 
OT-I/BLT1 /  cells (n   4 mice) or effector OT-I/BLT1 /  cells (n   5 mice). 
Cells recovered from the BAL on d 3 were analyzed by flow cytometry. 
(B) Effector OT-I/BLT1 /  and OT-I/BLT1 /  cells were analyzed for their 
ability to induce apoptosis of EL4 target cells as a function of increasing 
effector to target ratio. 
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tetramer specific for the OT-I TCR to analyze recruitment
of transferred OT-I/BLT1
 
 
 
/
 
 
 
 cells or OT-I/BLT1
 
 
 
/
 
 
 
 cells
into the BAL of CC10-OVA mice 3 d after transfer. These
experiments revealed a defect in recruitment of OT-I/
BLT1
 
 
 
/
 
 
 
 cells into the airway with a twofold reduction in
the number of tetramer-positive cells in the BAL of mice
that received OT-I/BLT1
 
 
 
/
 
 
 
 cells compared with mice that
received OT-I/BLT1
 
 
 
/
 
 
 
 cells (Fig. 4 A).
In the surviving mice that received OT-I/BLT1
 
 
 
/
 
 
 
 cells,
the transferred cells were still present in the BAL 14 d after
transfer; however, there was no histological evidence of
acute inflammation (unpublished data).
In addition to trafficking defects, studies have suggested
that LTB
 
4
 
 can influence the cytotoxicity of T cells (29, 30).
To assess this influence, we analyzed cytotoxicity using an in
vitro caspase activation assay. These experiments revealed a
small reduction (12%) in cytotoxicity with the OT-I/
BLT1
 
 
 
/  cells compared with OT-I/BLT1 /  cells (Fig. 4
B). Similar data were obtained if OT-I cells were treated
with the BLT1 inhibitor CP 105,696 (Fig. S2 C). This small
difference in cytotoxicity did not seem adequate to explain
the dramatic decrease in inflammation and mortality evident
when OT-I/BLT1 /  cells were used in this model. We
thus focused our subsequent experiments on the more signif-
icant defect we observed in the recruitment of OT-I/
BLT1 /  effector T cells.
To evaluate further the ability of BLT1 to mediate effec-
tor T cell recruitment in this model, we performed a com-
petitive homing assay by cotransferring Thy1.1 OT-I/
BLT1 /  cells and Thy1.2 OT-I/BLT1 /  into CC10-
OVA mice. In these experiments, an OT-I–specific tetramer
was used to identify the transferred cells, and the Thy1 anti-
gen was used to differentiate between transferred OT-I/
BLT1 /  (Thy1.1) cells and OT-I/BLT1 /  (Thy1.2) cells
in the same animals. This competitive homing assay provides
a sensitive test of BLT1-mediated recruitment in the model.
Figure 5. Recruitment of cotransferred OT-I/BLT1 /  cells and 
OT-I/BLT1 /  cells into the lung. (A) Representative flow cytometry of 
Thy1.1 OT-I/BLT1 /  and Thy1.2 OT-I/BLT1 /  effector cell recruitment into 
the BAL and lung 4 d after cotransfer into CC10-OVA mice. (B) The per-
centage of total OT-I cells that are Thy1.2 /BLT1 /  and Thy1.1 /BLT1 /  
that are recruited into the BAL and lung of CC10-OVA mice 4 d after 
cotransfer (n   4 mice; P   0.0001 for both BAL and lung). OT-I/BLT1 /  
cells were identified by Thy1.1  staining, and OT-I/BLT1 /  cells were 
identified by Thy1.2  staining within the CD8 /OT-I TCR-specific 
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Figure 6. Fibroproliferation and cellular recruitment in heterotopic 
tracheal transplants. (A) BLT1 RNA expression on murine CD3 /CD4  
and CD3 /CD8  lymphocytes isolated from heterotopic tracheal trans-
plants 1 or 2 wk after transplantation and compared with expression 
on naive CD3 /CD4  and CD3 /CD8  lymphocytes (cells pooled from 
12 tracheas at each time point). (B) Hydroxyproline content in heterotopic 
tracheal transplants harvested 2 and 3 wk after transplantation (n   4 
sets of 2 tracheas in each group). (C) Lymphocyte recruitment into tra-
cheas 7 d after transplant as assessed by flow cytometry (n   4 sets of 2 
tracheas in each group). (D) Activated lymphocyte recruitment (CD25 ) 
into tracheas 7 d after transplant as assessed by flow cytometry (n   4 
sets of 2 tracheas in each group).JEM VOL. 202, July 4, 2005 103
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Analysis of BAL and lung tissue 4 d after cotransfer revealed
a significant fourfold decrease in the recruitment of OT-I/
BLT1 /  cells into the lung and BAL compared with OT-I/
BLT1 /  cells (Fig. 5, A and B).
Role of BLT1 on airway fibroproliferation and obliteration
The results in this novel model of antigen-specific T cell–
induced lung injury suggests that BLT1-mediated lymphocyte
recruitment is important for the development of acute lung
rejection. However, because none of the mice that received
wild-type effector OT-I cells survived past 6 d, we were un-
able to evaluate the effects of disruption of the LTB4/BLT1
pathway on the development of airway obliteration and fi-
broproliferation as seen in OB. To assess this important com-
ponent of human lung transplant failure, we used two murine
tracheal transplant models that mimic the changes of OB. In
the first set of experiments, we used the heterotopic model of
OB in which tracheas from two syngeneic or allogeneic do-
nors are transplanted into the backs of wild-type or BLT1 / 
mice. The tracheas can be removed at various time points for
measurement of RNA expression, cellular recruitment, and
fibroproliferation. In the second set of experiments, we used
an orthotopic tracheal transplant model in which the alloge-
neic trachea is ligated to the native trachea of a wild-type or
BLT1 /  mouse with two end-to-side anastomoses (31). Af-
ter 2 wk, airway hyper-responsiveness can be measured, and
the tracheas can then be removed for histopathology.
BLT1 expression on T lymphocytes isolated from 
tracheal transplants
The first analysis we performed was the expression of BLT1
on CD3  T lymphocytes isolated from allogeneic hetero-
topic tracheal transplants into wild-type mice. For these ex-
periments, tracheas from BALB/c mice were transplanted
into C57BL/6 mice and harvested after 7 and 14 d. RNA
was isolated from cell-sorted CD3 /CD4  and CD3 /
CD8  lymphocytes from the transplanted tissue and then
analyzed by real-time QPCR. BLT1 expression levels were
compared with expression levels in naive CD4  and CD8 
T cells isolated from the spleens of C57BL/6 mice. BLT1
expression was up-regulated 15-fold on CD8  lymphocytes
and ninefold on CD4  lymphocytes isolated from tracheas 1
wk after transplantation. Two wk after transplantation,
BLT1 expression was up-regulated 180-fold on CD8  lym-
phocytes and 1.4-fold on CD4  lymphocytes isolated from
the transplanted tracheas (Fig. 6 A).
BLT1 deficiency in recipient animals reduced 
collagen deposition
Having demonstrated that BLT1 is highly induced on effec-
tor T cells recruited into tracheal allografts, we were inter-
ested in the role of BLT1 in the development of airway
fibroproliferation. To assess this role, we performed
heterotopic tracheal transplants into wild-type mice and
BLT1 /  mice. We analyzed the collagen content in trans-
planted tracheas by measuring hydroxyproline levels in
transplanted tracheas removed from recipients 2 and 3 wk af-
ter transplant. Allogeneic transplants into wild-type mice de-
velop significantly more fibrosis than syngeneic transplants at
2 and 3 wk as evidenced by greater hydroxyproline content
in the transplants (sixfold and twofold, respectively). Alloge-
neic transplants into BLT1 /  recipients had significantly less
fibrosis than allogeneic transplants into wild-type mice with
hydroxyproline values at 2 and 3 wk that were not statisti-
cally different from values in syngeneic transplants (Fig. 6 B).
BLT1 deficiency in recipient animals reduced recruitment 
of T lymphocytes
To determine if the difference in fibroproliferation seen in
BLT1 /  recipient mice compared with wild-type recipient
mice could be explained by differences in effector T cell traf-
ficking, we used flow cytometry to analyze T lymphocyte
recruitment into heterotopic tracheal transplants into wild-
type and BLT1 /  mice after 2 and 7 d. 2 d after transplanta-
tion there was minimal recruitment of T lymphocytes and
no difference between the groups (unpublished data). At 7 d,
however, there was a dramatic increase in the recruitment of
CD4  and CD8  lymphocytes into allogeneic transplants,
with 15% of the CD4  lymphocytes and 6% of the CD8 
lymphocytes also staining positive for the activation marker
CD25. Transplants into BLT1 /  mice had a statistically sig-
nificant twofold reduction in CD4  and threefold reduction
in CD8  lymphocyte recruitment compared with transplants
into wild-type mice (Fig. 6 C). Consistent with data in the
BLT1 /  mice, there was a significant reduction in CD4 
and CD8  lymphocyte recruitment into the allografts trans-
planted into wild-type mice treated with the BLT1-specific
inhibitor CP 105,696 when compared with mice treated
with vehicle alone (seven- and eightfold, respectively). Addi-
tionally, there was a significant fivefold and threefold reduc-
tion in activated CD4  and CD8  lymphocyte (defined by
CD25  staining) recruitment into allografts in BLT1 / 
mice (Fig. 6 D). Similar reductions were seen with treatment
of wild-type recipients with CP 105,696. Assessment of tis-
sue macrophage and neutrophil numbers by myeloperoxidase
levels and cell counts demonstrated only a 20% reduction in
neutrophil recruitment 1 d after transplantation in BLT1 / 
mice but no decrease at other time points (unpublished data).
BLT1 deficiency in recipient animals reduced obliteration 
of tracheal transplants
To assess further the role of BLT1 in airway obliteration, we
performed orthotopic tracheal transplants into BLT1 /  mice
or wild-type mice or, in some cases, wild-type mice treated
with vehicle or CP 105,696. In this model, the transplanted
trachea is ligated to the recipient animal’s native trachea with
two end-to-side anastomoses, thus preserving the movement
of air through the graft (31). This orthotopic model has sev-
eral advantages over the standard heterotopic model, includ-
ing the natural anatomic location of the graft, easier removalBLT1-MEDIATED T CELL TRAFFICKING IN LUNG REJECTION | Medoff et al. 104
for histologic analysis, and the ability to assess patency by an
indirect measurement of respiratory distress (enhanced pause
or Penh) (32). Allogeneic transplants into wild-type recipi-
ents developed prominent inflammation and fibroprolifera-
tion by 2 wk (Fig. 7 A, iii and iv), whereas syngeneic trans-
plants seemed to be normal at 2 wks (Fig. 7 A, i and ii).
Allogeneic transplants into BLT1 /  recipients had
minimal inflammation and fibroproliferation within the
airway lumen and attenuated inflammation and fibrosis in
the tissue surrounding the transplanted tracheas (Fig. 7 A, v
and vi). Transplants into wild-type mice treated with CP
105,696 (Fig. 7 A, ix and x) also had reduced fibroprolifer-
ation when compared with wild-type mice treated with
vehicle (Fig. 7 A, vii and viii). The epithelial cell layer
seemed to be normal in the syngeneic transplants (arrow in
Fig. 7 A ii.), was completely absent in the allogeneic trans-
plants (Fig. 7 A, iv and viii), and was present but seemed to
be damaged in transplants into BLT1 /  mice or wild-type
mice treated with CP 106,696 (arrow in Fig. 7 A, vi and
x). These data demonstrate that BLT1 contributes to air-
way epithelial cell injury and the development of OB. To
quantify better the degree of fibroproliferation, slides were
evaluated by an investigator blinded to the genotype of
each animal, and the degree of fibroproliferation was
scored on a scale of 0 to 4 (with 0 representing no oblitera-
tion of the tracheal lumen and 4 representing complete
obliteration of the lumen). Tracheas transplanted into allo-
geneic wild-type recipients had significantly higher fibro-
proliferation scores than tracheas transplanted into BLT1 / 
mice (threefold reduced) or wild-type mice treated with CP
105,696 (nearly twofold reduced) (Fig. 7 B).
In humans with OB, the obliteration and inflammation
of the airways leads to airflow obstruction and airway hy-
per-reactivity evident on pulmonary function tests and
methacholine testing (33). Similarly, the fibroproliferation
and inflammation that result from an allogeneic tracheal
transplantation in a mouse should lead to obstruction of
airflow and greater tracheal smooth muscle cell reactivity to
Figure 7. Representative histology and airways hyper-responsive-
ness 2 wk after orthotopic tracheal transplantations. (A) Representa-
tive (n   4) syngeneic tracheal transplants at (i) low (40x) and (ii) high 
magnification (400x). Representative (n   4) allogeneic tracheal trans-
plants into wild-type mice and wild-type mice treated with vehicle at low 
magnification (iii and vii) and high magnification (iv and viii). Allogeneic 
transplants into BLT1 /  mice and wild-type mice treated with CP 105,696 
at low magnification (v and ix) and high magnification (vi and x). The 
lumen of donor tracheas are marked with an asterisk. Arrows in ii, vi, and 
x indicate the airway epithelium. (B) Scoring of fibroproliferation in the 
lumens of the donor tracheas after orthotopic transplantation. The scoring 
was based on a scale of 0 (no fibroproliferation) to 4 (complete obliteration). 
N   4–6 animals/group. (C) Airways hyper-responsiveness as measured 
by Penh 2 wk after orthotopic tracheal transplant (n   8 mice/group; 
P   0.038 by repeated measures ANOVA between allogeneic transplants 
into wild-type mice and allogeneic transplants into BLT1 /  mice).JEM VOL. 202, July 4, 2005 105
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methacholine similar to effects in mice with allergic airway
inflammation (34). To test this obstruction of airflow and
tracheal smooth muscle cell reactivity, we measured the
Penh, a noninvasive measurement that uses airway pressure
and respiratory time to quantify respiratory distress in re-
sponse to methacholine administration (32). In this assay,
the allogeneic transplants into wild-type mice developed a
prominent increase in Penh consistent with increased air-
way resistance compared with syngeneic transplants (Fig. 7
C). This increase was abrogated completely when alloge-
neic transplantations were performed into BLT1 /  recipi-
ent mice, suggesting reduced obliteration and inflammation
of the transplanted tracheas (Fig. 7 C).
BLT1 expression on antigen-specific CD8  lymphocytes 
contributes to airway obliteration
Experiments in the CC10-OVA mice demonstrated that
BLT1 expression on CD8  lymphocytes plays a central
role in mediating antigen-specific acute lung injury. The
tracheal transplant experiments demonstrated that BLT1
expression in the recipient contributes to airway oblitera-
tion. Analysis of cellular recruitment in this model of OB
showed defects in CD4  T cell, CD8  T cell, and neutro-
phil recruitment into the allografts. Based on our findings
in our model of acute rejection, we hypothesized that ef-
fector CD8  lymphocytes were the major mediators of the
lung injury that stimulates airway fibroproliferation. Thus,
to link the results in these models better and to determine
if airway obliteration can be directly mediated by BLT1-
recruited CD8  T cells, we transplanted CC10-OVA tra-
cheas into MHC-matched C57BL/6 recipient mice that
had received effector OT-I cells. Because CC10-OVA tra-
cheas express the OVA transgene (unpublished data), trans-
fer of effector OT-I cells should induce rejection. Ortho-
topic tracheal transplants of CC10-OVA tracheas into
C57BL/6 mice demonstrated minimal fibroproliferation
(Fig. 8 A i).
 If we injected 2   106 activated OT-I/BLT1 /  effec-
tor cells into the recipients 24 h before the transplantation,
the tracheas developed moderate fibroproliferation after 2
wk (Fig. 8 A ii). However, if we injected 2   106 activated
OT-I/BLT1 /  effector cells into the recipients 24 h be-
fore transplantation, only minimal fibroproliferation was
seen (Fig. 8 A iii). Histology slides were evaluated by an
investigator blinded to the origin of the tissue, and the de-
gree of fibroproliferation was scored on a scale of 0 to 4.
Tracheas transplanted into recipients that received OT-I/
BLT1 /  cells had significantly higher fibroproliferation
scores than tracheas transplanted into recipients that re-
ceived OT-I/BLT1 /  cells (Fig. 8 B).
To quantitate further any differences in fibroprolifera-
tion, we analyzed hydroxyproline content in heterotopic
tracheal transplants performed with CC10-OVA tracheas
into MHC-matched C57BL/6 recipients that had received
2   106 activated OT-I/BLT1 /  effector cells or 2   106
activated OT-I/BLT1 /  effector cells 24 h before trans-
plantation. Tracheas were harvested 2 wk after transplanta-
tion. Tracheas transplanted into recipients that had re-
ceived OT-I/BLT1 /  effector cells had a significant
threefold increase in hydroxyproline content compared
with tracheas harvested from recipients that had received
OT-I/BLT1 /  effector cells (Fig. 8 C).
Figure 8. Fibroproliferation in transplanted tracheas after adoptive 
transfer of OT-I/BLT1 /  or OT-I/BLT /  cells. (A) Representative histology 
from orthotopic tracheal transplants of CC10-OVA mouse tracheas into 
C57BL/6 recipients after adoptive transfer of no cells (i), 2   106 OT-I/BLT1 /  
cells (ii), or 2   106 OT-I/BLT1 /  cells (iii) harvested 2 wk after transplan-
tation. (B) Scoring of fibroproliferation in the lumens of the donor tracheas 
after orthotopic transplantation. The scoring was based on a scale of 0 
(no fibroproliferation) to 4 (complete obliteration). N   3 animals/group. 
(C) Hydroxyproline content in heterotopic tracheal transplants of CC10-OVA 
mouse tracheas into C57BL/6 recipients after adoptive transfer of 2   106 
OT-I/BLT1 /  cells or 2   106 OT-I/BLT1 /  cells harvested 2 wk after trans-
plantation. N   3 sets of two tracheas in each group.BLT1-MEDIATED T CELL TRAFFICKING IN LUNG REJECTION | Medoff et al. 106
BLT1 on lung T lymphocytes isolated from human 
lung transplants
To determine if effector T cells that mediate human lung re-
jection express BLT1, we analyzed BLT1 expression on T
lymphocytes isolated from BAL fluid taken from surveillance
bronchoscopies of 40 lung transplant recipients using an an-
tibody to BLT1 and flow cytometry. These patients had un-
dergone transplantation at least 45 d earlier and were not
acutely ill. Eighteen patients were classified as clinically nor-
mal, 13 were diagnosed as having OB, and the rest were di-
agnosed as having either AR (n   2) or infection (n   9)
(excluded from analysis). The diagnosis of OB was based on
specific criteria published by the International Society of
Heart and Lung Transplantation that uses changes in pulmo-
nary function tests compared with baseline values (35, 36).
Characteristics of the patients in the two groups were not
different except for lung function, which was significantly
worse in the patients with OB (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20042481/DC1).
In addition, there were no significant differences be-
tween patients with and without OB in the time since
transplantation, the amount of fluid recovered, the number
of cells recovered, or total lymphocyte number recovered.
Cells isolated from the BAL were stained with antibodies to
CD3, CD4, CD8, and BLT1, and the percentage of CD4 
and CD8  lymphocytes expressing BLT1 was determined
by gating on either CD3 /CD4  or CD3 /CD8  lympho-
cytes. BLT1 was expressed on a significantly greater per-
centage of CD4  and CD8  lymphocytes isolated from pa-
tients with OB compared with normal patients (CD4 :
19   5.5% vs. 6   1.5%; CD8 : 26   7.8% vs. 4.5  
1.6%; Fig. 9, A and B).
DISCUSSION
Previous research into the role of LTB4 and its receptor
BLT1 in organ transplantation has been limited. In an animal
model of kidney transplantation, LTB4 was shown to be up-
regulated during acute allograft rejection (5), and inhibition
of 5-lipoxygenase significantly reduced rejection of kidney
allografts and prolonged graft function. In a heart transplant
model and a liver transplant model, blockade of BLT1 with a
chemical antagonist prolonged graft survival and reduced
mononuclear cell recruitment (6, 7). However, these studies
did not provide a clear mechanism for these findings and did
not specifically examine the role of LTB4-mediated T lym-
phocyte recruitment in rejection. Based on our recent data
demonstrating that BLT1 contributes to early T cell traffick-
ing to the airways in a mouse model of asthma, we hypothe-
sized that impaired T lymphocyte recruitment from inhibi-
tion of LTB4 activity may have been the major mechanism
behind the prolonged allograft function seen in these studies.
In the experiments reported here, we have found that
BLT1 is important for the development of CD8  T cell–
dependent airway rejection in a novel transgenic model of
acute lung rejection. In this model, OVA-specific effector T
cells transferred into CC10-OVA transgenic mice induced
airway injury and inflammation. Similar approaches have
been used to model heart and pancreatic islet rejection (28,
37). Using this model, we found that CC10-OVA trans-
genic mice that received BLT1 /  CD8  T cells had a re-
duction in the number of T cells recruited into the airway,
reduced airway inflammation, and a significant reduction in
mortality compared with CC10-OVA mice that received
wild-type OT-I effector T lymphocytes. OT-I/BLT1 / 
cells had similar activation and cytokine production com-
Figure 9. BLT1 expression on lymphocytes in human lung trans-
plants. (A) Representative flow cytometry data demonstrating BLT1 ex-
pression on CD4  and CD8  lymphocytes in a patient with normal lungs 
after transplant and a patient with OB. (B) BLT1 expression on CD4  and 
CD8  lymphocytes isolated from BAL fluid from lung transplant patients 
with normal lung function (n   18) and OB (n   13).JEM VOL. 202, July 4, 2005 107
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pared with wild-type OT-I cells; however, there was a small
defect in an in vitro assay of cytotoxicity consistent with
findings in previous studies (29, 30). Although reduced cyto-
toxicity may contribute to the phenotype in the model, we
believe that the primary mechanism for the reduced mortal-
ity was the defect in lymphocyte recruitment. These experi-
ments demonstrate that BLT1-mediated CD8  lymphocyte
recruitment into the airways is important for the develop-
ment of significant pulmonary inflammation and mortality in
this model and suggest that BLT1 may play a role in the de-
velopment of acute lung rejection after transplantation.
One of the important advantages of our new transgenic
model of acute lung rejection was that it allowed us to isolate
the mechanism of rejection to effector antigen-specific
CD8  T cells and thus explore the role of BLT1 for the re-
cruitment of the key cellular mediator of lung rejection. Al-
though CD4  T cells are clearly important for allorecogni-
tion and the development of the rejection response, CD8 
lymphocytes are recruited in greater numbers than CD4 
lymphocytes in acute lung rejection (38) and are considered
critical cellular mediators of graft injury (4). This new model
has the additional benefits of involving the entire lung with
intact vascular and lymphatic systems and allowing a physio-
logic assessment of graft failure in that the transfer of OT-I
effector cells into CC10-OVA mice induced lung rejection
and death within 6 d. This model differs from a previously
described transgenic mouse model of asthma in which alveo-
lar epithelial cells were engineered to secrete OVA into the
lung (39). In that model, foreign antigen was not found on
native lung cells, whereas in our new model OVA is mem-
brane bound on the airway epithelium, resulting in CD8  T
cell–mediated injury to the airway lining, which closely
mimics the pathophysiology of acute rejection. Our new
model also has an important difference from a transgenic
mouse model of viral pneumonia that used alveolar epithelial
cell expression of a viral antigen (influenza hemagglutinin) to
induce a pneumonitis after adoptive transfer of virus-specific
T cells (40). In our model, the foreign antigen is expressed
predominantly in the airways rather than in the alveoli, pro-
viding a model of acute bronchiolitis (the primary lesion in
acute lung rejection) rather than alveolitis (the primary lesion
in viral pneumonitis).
In human lung transplantation, clinical studies have
shown that acute rejection is the primary risk factor for the
development of chronic allograft dysfunction from OB,
which is the major cause of morbidity and mortality after
transplantation. To explore the role of BLT1 in the develop-
ment of OB, we used two murine models of airway obliter-
ation. In these experiments we have shown that BLT1 is ex-
pressed selectively on graft-infiltrating T lymphocytes and
that disruption of BLT1 signaling, either by genetic manipu-
lation or by a specific chemical antagonist, leads to reduced
airway fibrosis and obliteration (as assessed by histology, air-
way collagen content) and to airway hyper-reactivity (as as-
sessed by the Penh). Although there has been criticism of the
Penh in recent years (41), we believe the differences seen in
our experiments probably relate to the differences in tracheal
obliteration. The fact that syngeneic and BLT1 /  recipients
are breathing through two tracheas and the allogeneic recip-
ients have only one fully patent trachea should lead to differ-
ences in airway resistance, because the cross-sectional area of
the airways at the level of the trachea will be double in the
syngeneic and BLT1 /  hosts. In addition, airway inflamma-
tion leads to smooth muscle cell reactivity, so rejection may
make the tracheas more responsive to methacholine and lead
to more prominent narrowing compared with transplants
with little inflammation.
The most prominent defect noted in these models in
BLT1 /  mice or wild-type mice treated with the BLT1 in-
hibitor was a significant reduction in effector CD4  and
CD8  lymphocyte recruitment into the airways. There was
also a small difference in early neutrophil recruitment in the
model. Neutrophils are recruited into tracheal transplants in
response to surgical manipulation, ischemic injury, and dur-
ing acute rejection and may contribute to airway oblitera-
tion. Although our data demonstrate that LTB4 contributes
to neutrophil recruitment after transplantation, the defect in
effector lymphocyte recruitment in BLT1 /  mice was
more profound, suggesting that the effect on lymphocytes
was the major cause for the reduced airway fibrosis. To con-
firm this possibility, we performed experiments using CC10-
OVA mouse tracheal transplants into MHC-matched
C57BL/6 recipient mice that had received OVA-specific
BLT1 /  or BLT1 /  CD8  effector cells. Consistent with
findings by others (42), we found that CD8  T cell–medi-
ated injury was sufficient to induce fibroproliferation in
transplanted airways, although the fibroproliferation was less
than that seen with a complete MHC-mismatch transplant.
We also demonstrated that the transfer of BLT1 /  antigen-
specific CD8  effectors induced significantly less fibroprolifer-
ation compared with wild-type effector cells. These experi-
ments clearly demonstrate that the reduced fibroproliferation
seen in tracheal transplants into BLT1 /  recipients result at
least in part from effects on CD8  lymphocyte recruitment
separate from effects on neutrophil recruitment.
We have correlated our findings in these mouse models
of OB to the disease state in humans by demonstrating the
expression of BLT1 on graft-infiltrating lymphocytes isolated
from the lungs of patients after lung transplantation. When
compared with patients with normal lungs after lung trans-
plantation, the percentage of T cells expressing BLT1 was
significantly higher in the lymphocytes isolated from patients
with OB. These data suggest that the LTB4/BLT1 pathway
may play a role in the recruitment of pathogenic T cells into
the lungs during the development of OB.
In previous experiments, we found that BLT1 contrib-
uted to early T cell recruitment into the airways in a murine
model of asthma (3); however, this defect did not affect late T
cell recruitment, the overall development of airway inflam-
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gan transplantation, however, early epithelial cell injury me-
diated by graft-specific T cells is a primary factor driving
acute rejection and the development of chronic organ dys-
function such as OB (43), and thus defects in early lympho-
cyte recruitment may have a greater impact on the overall pa-
thology. Therefore, our findings suggest that disruption of
BLT1 expression on CD8  T cells will reduce their recruit-
ment into the airway and possibly reduce their cytotoxicity,
leading to reduced T lymphocyte–mediated epithelial cell in-
jury. This reduced epithelial cell injury then leads to reduced
airway obliteration. The data in human lung transplant recip-
ients correlate with the findings in the animal models and
suggest that the LTB4/BLT1 pathway may be involved in re-
cruiting T cells into the airways of humans with OB.
In summary, we have shown that the LTB4/BLT1 path-
way provides an important signal for the recruitment of T
lymphocytes into the airway. Our findings suggest that dis-
ruption of LTB4/BLT1 signaling will decrease the intensity
of rejection and inhibit the formation of OB. It has been
suggested that measures that reduce the intensity of AR
could have profound effects on long-term allorecognition,
allowing the development of tolerance to allografts (44).
Thus, inhibition of BLT1 may have a therapeutic role by
limiting the injury associated with rejection, delaying the
progression to OB, and potentially allowing the induction of
tolerance to lung transplants.
MATERIALS AND METHODS
Mice. Wild-type BALB/c and C57BL/6 mice were purchased from
Charles River Laboratories Inc. The OT-I TCR transgenic mouse strain in
the C57BL/6-Thy1.1 background was provided by P. Shrikant (Roswell
Park Cancer Institute, Buffalo, NY), and OT-I TCR mice in the C57BL/6-
Thy1.2 background were obtained from Jackson Immunoresearch Labora-
tories. BLT1-deficient mice (BLT1 / ) were generated in our laboratory
and backcrossed into C57BL/6 for nine generations (45). These mice were
then crossed with OT-I mice to generate OT-I/BLT1 /  mice. Mice were
used at 8–12 wk of age. All protocols were approved by the Massachusetts
General Hospital Subcommittee on Research and Animal Care.
Generation of CC10-OVA mice. The transferrin receptor–OVA con-
struct in the pcDNA3.1V5-His6-TOPO plasmid (Invitrogen) was made as
previously described (28). This construct was then ligated to the lung-spe-
cific promoter for CC10 (provided by J. Whitsett, University of Cincinnati,
Cincinnati, OH) (Fig. 1 A). The construct was successfully injected into
pronuclei of C57BL/6 eggs, implanted into C57BL/6 pseudopregnant fe-
males, and a founder mouse line was then expanded.
BAL analysis from patients after lung transplantation. The proto-
col was reviewed and approved by the Massachusetts General Hospital Hu-
man Studies Committee. BAL samples were taken from patients undergo-
ing surveillance bronchoscopy after lung transplantation. Patients were
classified by clinicians blinded to the analysis as normal after transplantation,
AR, OB, or infected. AR patients were diagnosed based on transbronchial
biopsies, infected patients by a positive culture or serology in the proper
clinical setting, and OB patients were diagnosed based on specific published
clinical criteria (35, 36). Only patients with OB stage 1 or higher were clas-
sified as OB. The cells were isolated from the fluid and incubated with an
unconjugated anti-human BLT1 mAb (Serotec Ltd.). The samples were
then stained with a secondary mAb conjugated to PE. The cells were also
stained with mAb to CD3, CD4, and CD8 (BD Biosciences). Staining was
analyzed using a FACSCalibur analytical flow cytometer (Becton Dickin-
son) and Flowjo software (Tree Star, Inc.).
OT-I cell preparation and adoptive transfer. Isolation and prepara-
tion of OT-I and OT-I/BLT1 /  CD8  effector T cells were performed as
described previously (28). Cells were resuspended in PBS, and 5   105 cells
were injected intraperitoneally.
Orthotopic and heterotopic tracheal transplants. Orthotopic trans-
plants were performed as described (31). Briefly, donor mice received a lethal
ketamine injection (100 mg/kg) followed by sterile removal of the trachea.
Recipient mice were anesthetized using ketamine (80 mg/kg)/xylazine (12
mg/kg). The trachea was exposed, and openings were made in the distal tra-
chea and the proximal trachea. The donor trachea was anastomosed to the
openings using 10–0 polypropylene suture. For the heterotopic transplanta-
tions, two donor tracheas were implanted subcutaneously in the back of the
recipient mouse as described (46). Some mice were given CP 105,696, a small-
molecule antagonist of BLT1 (provided by H. Showell of Pfizer Inc.) (24). 10
mg/kg of CP 105,696 was administered by gavage suspended in a vehicle solu-
tion of 10% ethanol/0.45% methylcellulose/0.45% Tween 80. Control mice
were given vehicle alone. In certain experiments, 2   106 effector OT-I or
OT-I/BLT1 /  cells were injected intraperitoneally into recipient animals 24 h
before transplantation. Mice were killed at various time points for analysis.
Airway responsiveness. Airway hyperresponsiveness was measured non-
invasively using a whole-body plethysmograph (Buxco Electronics) as pre-
viously described (34).
Chemotaxis. Chemotaxis was performed using a 96-well chemotaxis
plate (Neuroprobe Inc.) as previously described (47). For the inhibitor stud-
ies, CP 105,696 was added both the upper and lower chambers of the plate
to give the indicated concentration.
OT-I cell cytotoxicity. Cytotoxicity was measured using a commercially
available kit according to the manufacturer’s protocol (CyToxiLux Plus, On-
coImmunin, Inc.). Briefly, EL4 target cells were suspended in PBS at 2   106
cells/ml in the presence of a fluorescent target cell marker and then incubated
in a 37 C for 1 h with or without OVA peptide (2  g/ml). The target cell
suspension was then cultured with effector cells at the various effector cell/
target cell ratios. The cells were then incubated in caspase substrate for 1 h.
The cells then were analyzed by flow cytometry. In other experiments, both
the target cells and the T cell effectors were treated with increasing concentra-
tions of the BLT1 inhibitor, CP 105,696 in a 2:1 effector cell/target cell ratio.
CC10-OVA mouse tissue sampling and processing. Animals were
killed with a lethal injection of ketamine (100 mg/kg). The lungs were la-
vaged with six 0.5-ml aliquots of PBS containing 0.6 mM EDTA. The
spleen and thoracic lymph nodes were removed. The lungs were flushed
free of blood by slowly injecting 10 ml of PBS into the right ventricle be-
fore excision for all studies.
Histopathologic examination. Tissue was placed into 10% buffered for-
malin. Multiple paraffin-embedded 5- m sections were prepared and
stained with hematoxylin and eosin. The slides were evaluated by light mi-
croscopy, and the amount of fibroproliferation was assessed using a 0-to-4
scale given by an investigator blinded to the genotype of the animals.
Tissue digests and isolation of single cell suspensions. Lung, tra-
chea, or spleen was excised and minced into small pieces with a scissors. The
pieces were digested for 45 min in RPMI with 0.28 Wunsch U/ml Liberase
Blendzyme (Roche) and DNase 30 U/ml (Sigma-Aldrich) for 45 min at
37 C. The digested tissues were then extruded through a mesh strainer.
Flow cytometry and cell sorting. Cells recovered from culture, BAL,
or suspensions of trachea, lung, lymph node, spleen, or lung were stainedJEM VOL. 202, July 4, 2005 109
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and analyzed as previously described (34). The tetramer specific for OT-I
cells was obtained from Beckman Coulter. The anti-perforin antibody was
from eBioscience. All other antibodies were from BD Biosciences. Single-
cell suspensions of 12 combined tracheas were stained and sorted using a
FACSVantage cell sorter.
Real-time PCR. Total RNA was isolated and analyzed by real-time
PCR using MX-4000 software (Stratagene) as previously described (48).
Specific primers used for sequence detection of message for the BLT1 gene
are 5 -GCTCACTGCTCCCTTTTTCCT-3  and 5 -GCGGCAAC-
CCATCTCTCTAA-3  and for the GAPDH gene are 5 -GGCAAAT-
TCAACGGCACAGT-3  and 5 -AGATGGTGATGGGCTTCCC-3 .
Fibroproliferation. Hydroxyproline was assayed as described (49).
Myeloperoxidase. Myeloperoxidase was assayed as described (50).
Online supplemental material. Fig. S1 shows the expression of
CD25, CD62L, and IFN  on BLT1 /  and BLT1 /  OT-I effecter CD8 
lymphocytes. Fig. S2 includes additional data quantifying expression of
BLT1 by effector OT-I cells, measuring chemotaxis of these cells to LTB4,
and measuring the cytotoxicity of these cells in an in vitro caspase assay. Ta-
ble S1 includes background data on the transplant patients studied including
their average lung function. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20042481/DC1.
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